COO

Business profile & competitive position

The Cooper Companies, Inc. operates in the Healthcare sector, specifically the Medical – Instruments & Supplies industry. Its classification places it alongside producers of medical devices, consumable supplies, and related equipment sold through healthcare providers, retailers, and direct channels. The first thing the numbers say about its competitive position is that current profitability is restrained: the trailing net margin is 5.6% and return on equity is 2.8%. These are not the figures typically associated with a deep, self-reinforcing moat. A 2.8% ROE means the company is generating only modest returns on its book equity, while a 5.6% net margin leaves limited room for error after covering manufacturing, R&D, sales, and acquisition-related costs. That profile is consistent with an industry where pricing is disciplined by regulators, group purchasing organizations, and large retail partners rather than one where a single producer can extract outsized rents indefinitely. The low beta of 0.82 also suggests the stock behaves more like a defensive, mature healthcare name than a high-growth disruptor.

Financial posture

Cooper carries a market capitalization of $14.8 billion and trades at a P/E ratio of 64.2. That multiple is unusually high relative to its near-term profitability: net margin is just 5.6% and ROE is 2.8%. In practice, a 64.2 P/E implies the market is pricing in substantial earnings recovery or long-term growth that is not yet visible in the current margin structure. The beta of 0.82 tells the same relative-stability story: the stock tends to move less sharply than the overall market, which is common for healthcare suppliers but somewhat at odds with the premium multiple. With only the figures supplied here, leverage cannot be quantified, so valuation risk should be viewed mainly through the lens of how much future growth is already embedded in the share price. Anyone studying the name should treat the current valuation as the central tension: high expectations versus still-normalized earnings power.

Macro & geopolitical exposure

Because COO sits in the Medical – Instruments & Supplies industry, its macro exposure is shaped by forces common to medical-device and supply companies. Regulatory risk is central: product approvals, recalls, quality inspections, and evolving FDA or international standards can alter costs and revenue timing. Reimbursement pressure is another constant, since insurers, government payers, and hospital systems negotiate pricing for the categories in which the company competes. On the trade side, many instruments and disposable supplies rely on global supply chains, so tariffs, shifts in U.S.-China trade policy, shipping costs, and currency translation can affect both input costs and overseas revenue. Commodity prices for plastics, resins, and packaging materials feed directly into margins. Finally, demographic aging supports long-term demand, while fertility trends and elective-procedure sensitivity can create shorter-term demand swings. These are sector-level dynamics rather than company-specific forecasts, but they define the operating climate in which Cooper competes.

Recent developments

The most recent COO-specific headline in the data batch came on August 5, 2026, when Zacks.com published “The Cooper Companies (COO) Upgraded to Buy: Here's What You Should Know.” That upgrade is a notable sentiment marker heading into the company’s next report, though it does not represent an operational development. The same earnings-intelligence window also captured unrelated reports: Gurufocus.com covered Motorola Solutions’ Q2 2026 record sales and raised guidance on August 6, 2026; Assurant’s Q2 2026 record results on August 5, 2026; and Global Payments’ Q2 2026 progress amid Middle East headwinds, also on August 5, 2026. These other stories do not directly affect Cooper’s fundamentals, but they illustrate that the broader Q2 2026 reporting period included a mix of strong results and geopolitically driven caution.

Earnings behavior & post-earnings drift

Cooper has delivered a flawless earnings beat rate over the last eight reported quarters: 8 out of 8, or 100%. The average earnings surprise across that span is 4.6%. Yet the stock’s post-earnings drift has been mildly negative, with the average 5-day move after reports registering at -0.91% and classified as a downward drift. The pattern is visible in the most recent quarters:

• June 4, 2026: EPS of $1.21 versus a $1.10 estimate, a 10.0% surprise. The stock rose 8.58% the next day and 8.85% over the following five days.
• March 5, 2026: EPS of $1.10 versus a $1.03 estimate, a 6.8% surprise. The stock fell 4.55% the next day and 10.82% over the following five days.
• December 4, 2025: EPS of $1.15 versus a $1.11 estimate, a 3.6% surprise. The stock rose 5.67% the next day and 6.59% over the following five days.
• August 27, 2025: EPS of $1.10 versus a $1.07 estimate, a 2.8% surprise. The stock fell 12.86% the next day and 8.24% over the following five days.

The takeaway is that beating the official estimate has not guaranteed upward price follow-through. Two of the last four reports produced sharp five-day selloffs despite positive surprises, suggesting the market’s real expectation may run above the published consensus. The unofficial consensus for the next report, scheduled for September 9, 2026 after the close, sits at $1.12. At a price of $75.76 and an RSI of 64.6, the stock is also approaching technically overbought territory, which can amplify post-news reversals.